Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Paraproteinemias 1Nervous System Diseases 1Kidney Diseases 1Hematologic Diseases 1Autoimmune Diseases 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Plasma Exchange × Clear all
NCT01210716 2013-09-23

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Fenwal, Inc.

Phase 3 Completed
37 enrolled 7 charts
Genitourinary

Autoimmune Diseases, Hematologic Diseases, Kidney Diseases, Nervous System Diseases, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡